

**Black Box Warning: Hepatotoxicity:** monitor LFTs before treatment and monthly; if liver transaminases  $>5 \times$  IULN, withhold until transaminase levels return to  $<2.5 \times$  IULN

• **Myelosuppression:** Monitor CBC  $\times 2$  mo, then monthly, differential, platelet count; for bleeding: epistaxis, rectal, gingival, upper GI, genital and wound bleeding; **tumor-related hemorrhage may occur rapidly**

• ANC and platelets: if ANC  $<1 \times 10^9/L$  and/or platelets  $<50 \times 10^9/L$ , stop until ANC  $>1.5 \times 10^9/L$  and platelets  $>75 \times 10^9/L$

• **Electrolytes:** calcium, potassium, magnesium, sodium; lipase, phosphate; hypokalemia, hypomagnesemia should be corrected before use

• AST/ALT/bilirubin/lipase/amylase: if increased to grade 3, withhold product; resume at 400 mg daily when levels return to grade 1 or below

• **Pregnancy/breastfeeding: do not use in pregnancy, breastfeeding**

**Evaluate:**

• Therapeutic response: decrease in progression of disease

**Teach patient/family:**

• **Infection: to report immediately cough, fever, chills**

• To report bleeding gums; blood in stools, urine, emesis

• About reason for treatment, expected results

• That many adverse reactions may occur

• To avoid persons with known upper respiratory tract infections; immunosuppression is common

• To watch for signs, symptoms of low potassium or magnesium

• To notify prescriber of all OTC, prescription, and herbal products used; not to receive vaccinations without prescriber's approval

• **Pregnancy/breastfeeding: to use contraception during treatment; not to breastfeed**

**⚠ HIGH ALERT**

**RARELY USED**

**niraparib**

(nye-rap'-a-rib)

Zejula

*Func. class.:* Antineoplastic

**USES:** Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

**DOSAGE AND ROUTES**

• **Adult: PO** 300 mg/day until disease progression or unacceptable toxicity. Begin therapy no later than 8 wk after last platinum-containing regimen

**RARELY USED**

**nisoldipine (Rx)**

(nye-sole'dih-peen)

Sular

*Func. class.:* Calcium channel blocker, antihypertensive

*Chem. class.:* Dihydropyridine

**USES:** Essential hypertension, alone or in combination with other antihypertensives, ischemic heart disease

**CONTRAINDICATIONS:** Hypersensitivity to this product or dihydropyridines; sick sinus syndrome; 2nd-/3rd-degree heart block; aortic stenosis

**DOSAGE AND ROUTES**

**Hypertension**

• **Adult: PO** 17 mg/day initially, may increase by 8.5 mg/wk, usual dose 17-34 mg/day, max 34 mg/day

• **Geriatric/hepatic dose: PO** 8.5 mg/day, increase based on patient response

**Variant (Prinzmetal's) angina/stable angina pectoris (unlabeled)**

• **Adult: PO** 17-34 mg/day, max 34 mg/day